News|Articles|September 18, 2024

Conference Compendium: The Top 10 Takeaways From ESMO 2024

ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.

At the 2024 European Society of Medical Oncology (ESMO) Congress, researchers from across the world gathered to present updated findings on various anti-cancer treatment modalities for several different patient populations. Specifically, many oral presentations from the meeting focused on therapeutic strategies that have the potential to improve outcomes across the breast and lung cancer fields.

Related to this article

$Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer$

September 28th, 2026

Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer

10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.

October 5th, 2026

Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.

Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.

October 5th, 2026

Balancing Cure and Toxicity in Complex Lung Cancer Radiotherapy Regimens

Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.

October 4th, 2026

How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?

Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.

At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.

October 4th, 2026

Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer

At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.

October 3rd, 2026

Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery

Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.

Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.

October 3rd, 2026

Rectal Spacers May Reduce Toxicity of Proton Therapy in Prostate Cancer

Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.

Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.

October 2nd, 2026

Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups

Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.